Semaglutide and Pregnancy: Safety, Risks, and What to Do

Most people who use semaglutide for weight loss are women between 25 and 50. Many of them are at a stage of life where pregnancy is possible, planned, or being considered. That makes one question come up constantly: is it safe to take semaglutide while pregnant, or while trying to get pregnant?

The direct answer is no. Semaglutide is contraindicated during pregnancy and should be stopped well before you try to conceive. But that one-sentence answer leaves out a lot of important context. It misses the timing question, the fertility conversation, the contraception piece, and what to do if you unexpectedly become pregnant while on a GLP-1 medication.

This article covers all of it, clearly and honestly.

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Always consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Is Semaglutide Safe During Pregnancy?

No. Semaglutide is not considered safe to use during pregnancy based on current evidence, and the FDA prescribing information for branded semaglutide products states clearly that it should be discontinued when pregnancy is confirmed or planned.

The concern comes from preclinical animal studies. In reproductive toxicology studies conducted in rats and rabbits, semaglutide caused adverse fetal development outcomes, including structural abnormalities and reduced fetal weight, at doses comparable to human therapeutic levels. These findings triggered the standard precautionary language in the prescribing information: based on animal data, semaglutide may cause fetal harm when administered to a pregnant woman.

There are no adequate, well-controlled studies of semaglutide in pregnant humans. This is not unusual for medications developed in the past decade. Pregnant women are routinely excluded from clinical trials. The absence of human data does not mean the drug is safe in pregnancy. It means we do not have the evidence to know, and given the animal signals, the appropriate clinical position is to avoid use entirely.

This applies to all GLP-1 receptor agonists in the same drug class, including tirzepatide and liraglutide. The entire class carries similar reproductive toxicology findings and similar recommendations against use during pregnancy.

---

Why You Need to Stop Semaglutide Before Conceiving

The FDA prescribing information for branded semaglutide products recommends stopping the medication at least 2 months before a planned pregnancy. This guidance is specific and has a clear pharmacological rationale.

Weekly injectable semaglutide has a half-life of approximately 7 days. This is unusually long for an injectable medication. Because of that long half-life, semaglutide takes considerably longer to clear your system than most medications. Following standard pharmacokinetic calculations, full elimination takes roughly 5 to 7 weeks after the last dose.

The 2-month recommendation builds in a safety margin on top of that clearance window. The goal is to ensure that by the time conception occurs, semaglutide levels are undetectable and the critical early weeks of embryonic development occur without any drug exposure.

Early fetal development, particularly the first 8 to 12 weeks of pregnancy, is when organ formation happens. This is when the embryo is most vulnerable to anything that could interfere with normal cellular growth and differentiation. The 2-month washout before conception is designed to keep that window clean.

If you are considering pregnancy in the next several months, this timeline has real practical implications. You need to have a conversation with your prescribing provider now, not after a positive pregnancy test.

---

What Happens If You Become Pregnant While Taking Semaglutide?

Stop the medication immediately and contact your healthcare provider the same day.

This is not a cause for panic, but it requires immediate action. Early discontinuation limits the duration of any fetal exposure. Your provider will advise on next steps, which typically include confirming the pregnancy, establishing prenatal care, and notifying your OB or midwife about prior medication use.

If you have been using semaglutide and discovered a pregnancy in the early weeks, the exposure window may have been limited. That does not guarantee there is no risk, but earlier discontinuation is meaningfully better than continuing the medication into the second or third trimester.

Do not wait for your next scheduled appointment. Call your provider as soon as you have a positive test.

There is also a pregnancy registry. Novo Nordisk maintains a pregnancy exposure registry for semaglutide to collect safety data on pregnancies where exposure occurred. Your provider can give you information about enrollment. Contributing to that registry helps build the evidence base that currently does not exist for this drug class in human pregnancy.

---

Semaglutide, Weight Loss, and Fertility: The PCOS Connection

Here is where the picture becomes more nuanced. While semaglutide is contraindicated during pregnancy, its use before conception may actually improve fertility for a significant subset of women, particularly those with polycystic ovary syndrome (PCOS).

PCOS affects approximately 8 to 13 percent of women of reproductive age and is one of the most common causes of ovulatory infertility. Insulin resistance and excess adipose tissue drive much of the hormonal disruption in PCOS, including elevated androgens, irregular cycles, and anovulation. Weight loss consistently improves these parameters, even modest weight loss of 5 to 10 percent of body weight.

The connection between semaglutide-facilitated weight loss and fertility improvement is increasingly supported by clinical research. A study published in the Journal of Clinical Endocrinology and Metabolism found that GLP-1 receptor agonists improved ovulatory function and reproductive hormone profiles in women with PCOS, independent of weight loss effects, suggesting a direct mechanism as well as an indirect one through adiposity reduction. (Lamos EM et al., 2017)

The classic foundation for this relationship was established by Clark AM and colleagues in a landmark paper in Human Reproduction, which showed that modest weight loss in obese anovulatory women resulted in resumption of ovulation and significantly improved pregnancy rates without fertility medications. (Clark AM et al., Hum Reprod. 1995;10(10):2705-12)

What this means practically: if you are using semaglutide for weight loss and have PCOS or obesity-related anovulation, your fertility may improve during treatment. This is medically positive and important to plan for, not ignore. Improved fertility while on semaglutide means an unintended pregnancy is more likely than it might have been before you started treatment.

---

Contraception While on Semaglutide: What You Need to Know

Because semaglutide can improve fertility in women who previously had irregular cycles or anovulation, effective contraception during treatment is essential if you are not actively trying to conceive.

Two points are worth understanding about contraception and GLP-1 medications.

First, the general principle: if pregnancy is not your goal during semaglutide treatment, use reliable contraception. The same applies during the 2-month washout period before attempting conception. Consult your provider about the contraceptive method that fits your situation.

Second, a specific note on oral contraceptives: semaglutide slows gastric emptying, which can theoretically affect the absorption of oral medications, including combined oral contraceptives. Novo Nordisk has conducted pharmacokinetic studies evaluating this interaction. Those studies found that weekly injectable semaglutide did not meaningfully reduce the bioavailability of oral contraceptive hormones in healthy volunteers. However, individual variation exists, and your prescribing provider may have specific guidance based on your medication and dosing schedule.

If you use oral contraceptives, inform both your GLP-1 prescriber and your gynecologist about your full medication list. Long-acting reversible contraceptives (IUDs, implants) avoid the oral absorption concern entirely if that is a preference.

---

Planning a Pregnancy After Semaglutide

Stopping semaglutide before conception does not mean abandoning the progress you have made. It means transitioning thoughtfully.

A few practical considerations for that transition:

Timing and weight stability. When you stop semaglutide, appetite typically returns as the medication clears. Some weight regain is common, particularly in the weeks immediately following discontinuation. Discussing a maintenance strategy with your provider before stopping gives you the best foundation for the washout period and early pregnancy. Some providers recommend a dietary and behavioral maintenance plan to bridge the gap.

Prenatal nutrition. Pregnancy nutritional needs are different from weight loss nutritional needs. Begin prenatal vitamins (particularly folic acid at least one month before conception) before you start trying. Your OB or midwife will have specific recommendations.

Discussing your history. When you establish prenatal care, disclose your full medication history, including semaglutide use and the approximate stop date. This context helps your care team assess your pregnancy appropriately.

No rush required. Nothing in the current evidence suggests that having used semaglutide for weight loss creates ongoing risk to a future pregnancy, provided the washout period has been completed. You are not in a race to conceive immediately before any effect of prior use could theoretically persist. The 2-month window exists precisely to eliminate that concern.

---

How Prescriva Handles Pregnancy Situations

Prescriva does not prescribe semaglutide or any GLP-1 medication to patients who are currently pregnant. Every intake process includes questions about current pregnancy and pregnancy plans.

If you become pregnant while receiving GLP-1 treatment through Prescriva, contact your prescribing provider immediately. The provider will discontinue the prescription and advise on next steps.

If you are planning a pregnancy, raise that directly with your provider during your next check-in. A planned approach, including establishing a discontinuation timeline and building a maintenance strategy, is better for you than an abrupt stop with no plan.

---

Bottom Line

Semaglutide is not appropriate to use during pregnancy, and current FDA guidance recommends stopping at least 2 months before attempting to conceive. This timeline accounts for the drug's long half-life and ensures the embryo is not exposed during early organ formation.

If you become pregnant while taking semaglutide, stop immediately and contact your provider that day.

The fertility picture is more complex. For women with PCOS or obesity-related cycle irregularities, semaglutide-facilitated weight loss may improve fertility. That is a real clinical benefit and a real reason to use contraception reliably during treatment if pregnancy is not your goal.

The 2-month washout, reliable contraception during treatment, and a planned transition conversation with your provider cover the key bases. None of this requires you to choose between treating your weight and eventually having children. It requires planning and honest communication with your care team.

*This article does not constitute medical advice. Compounded semaglutide is not FDA-approved. Results vary. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

*Reviewed by the Prescriva Medical Team. This article is pending Compliance Officer review prior to publication.*

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021 Mar. PMID 33567185. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Lamos EM, et al. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. *Expert Rev Clin Pharmacol.* 2017 Apr. PMID 28276778. [https://pubmed.ncbi.nlm.nih.gov/28276778/](https://pubmed.ncbi.nlm.nih.gov/28276778/)
3. Clark AM, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod.* 1995 Oct. PMID 8567797. [https://pubmed.ncbi.nlm.nih.gov/8567797/](https://pubmed.ncbi.nlm.nih.gov/8567797/)